Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Pulmatrix Operating Company Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners and 2 art units, indicating separate prosecution paths.
BURKE, MATTHEW RYAN is the busiest examiner, with 1 pending matter. Counsel should tailor responses to each application while maintaining consistency in the underlying pharmaceutical and biotechnology positions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKE, MATTHEW RYAN | 1 | 0.0% | +0.0% |
| ABBAS, ABDULRAHMAN MUSTAFA | 1 | 51.6% | +29.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19107206 | METHODS OF USING ITRACONAZOLE DRY POWDERS | BURKE, MATTHEW RYAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17048491 | ANTIFUNGAL FORMULATIONS FOR PULMONARY ADMINISTRATION COMPRISING ITRACONAZOLE | ABBAS, ABDULRAHMAN MUSTAFA | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19107206 | METHODS OF USING ITRACONAZOLE DRY POWDERS | BURKE, MATTHEW RYAN | 1619 | §102§103Other | Non-Final OA | — | Pending | Feb 27, 2025 |
| 17048491 | ANTIFUNGAL FORMULATIONS FOR PULMONARY ADMINISTRATION COMPRISING ITRACONAZOLE | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103 | Final Rejection | — | Pending | Oct 16, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPulmatrix Operating Company Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Matthew Ryan Burke has the most, with 1 of Pulmatrix Operating Company Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
